- Home
- NGD vs TGTX Comparison
NGD vs TGTX Comparison
Compare NGD & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NGD | TGTX |
|---|---|---|
| Founded | N/A | 1993 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.3B | 5.5B |
| IPO Year | 2004 | 1995 |
Fundamental Metrics
Financial Performance| Metric | NGD | TGTX |
|---|---|---|
| Price | $8.85 | $29.73 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $8.75 | ★ $54.75 |
| AVG Volume (30 Days) | ★ 16.1M | 1.4M |
| Earning Date | 02-18-2026 | 11-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1232.42 | N/A |
| EPS | 0.31 | ★ 2.78 |
| Revenue | ★ $1,242,200,000.00 | $531,898,000.00 |
| Revenue This Year | $62.14 | $87.88 |
| Revenue Next Year | $57.44 | $48.75 |
| P/E Ratio | $28.22 | ★ $11.00 |
| Revenue Growth | 44.19 | ★ 100.88 |
| 52 Week Low | $2.43 | $25.28 |
| 52 Week High | $9.59 | $46.48 |
Technical Indicators
Market Signals| Indicator | NGD | TGTX |
|---|---|---|
| Relative Strength Index (RSI) | 59.80 | 39.73 |
| Support Level | $8.68 | $29.79 |
| Resistance Level | $9.52 | $31.37 |
| Average True Range (ATR) | 0.51 | 0.97 |
| MACD | 0.03 | -0.04 |
| Stochastic Oscillator | 64.16 | 8.21 |
Price Performance
Historical ComparisonAbout NGD New Gold Inc.
New Gold Inc participates in the development and operation of intermediate mining properties. The company has a portfolio of two primary assets which are also its operating segments: the Rainy River Mine and the New Afton Mine in Canada. The company also owns the Cerro San Pedro Mine in Mexico. The company derives revenue from the sale of gold, copper, and silver.
About TGTX TG Therapeutics Inc.
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.